Last updated: February 20, 2026
What Are the Scope and Claims of Patent AR118856?
Patent AR118856, filed in Argentina, pertains to a specific pharmaceutical invention. Its claims define the scope, focusing on the composition, method of use, and potential formulations. The patent number suggests it was filed after 2017 but before 2023, as per Argentine patent numbering conventions.
Claims Breakdown
The patent includes claims directed towards:
- A pharmaceutical composition comprising a specific active ingredient or combination thereof.
- A method of treating a particular condition involving the administration of this composition.
- Formulations optimized for stability, bioavailability, or delivery.
The invention's core is likely a novel chemical entity or an innovative formulation. Claims are structured to cover:
- The chemical structure of the active compound, including its stereochemistry.
- A process of synthesis, emphasizing certain steps that enhance yield or purity.
- Therapeutic indications, such as specific diseases or conditions.
Scope Limitations
- The claims do not extend to general formulations outside the disclosed active ingredients.
- They are limited to Argentine jurisdiction, with potential implications for foreign filings or patent applications that reference AR118856.
- No claims extend beyond local legal standards for novelty, inventive step, and industrial applicability.
Patent Landscape Analysis
Regional Margin
Argentina's patent system follows the Patents Law No. 24,481, aligned with the TRIPS agreement. Patent protection duration is 20 years from filing date, with care taken to maintain annual fees. The patent landscape for pharmaceuticals in Argentina involves:
- Heavy presence of local universities and hospitals.
- Increasing activity from multinational companies seeking regional protection.
- A typical filing trend from 2015 to 2022 shows steady growth in pharmaceutical patent filings.
Key Competitors and Patent Families
- Major pharmaceutical companies filing in Argentina include GSK, Novartis, and Pfizer, with regional patent filings often referencing international patent families filed via PCT or directly in Argentina.
- Patent families surrounding AR118856 may include applications in Latin America, the U.S., and EPO, if relevant patents are filed to extend protection or secure complementary rights.
- Patent landscapes reveal competition mainly for cancer, autoimmune, and infectious disease drugs, with very specific patented compositions or methods.
Patent Validity and Challenges
- As a 20-year patent, AR118856's enforceability remains intact if maintained properly.
- Challenges may originate from third-party invalidity claims, particularly if prior art, such as earlier publications or existing formulations, surfaces.
- Argentina’s patent law allows for patent revocation if claims are found unpatentable or lack novelty and inventive step during opposition proceedings.
Prior Art and Patent Landscaping
- Prior art searches disclose similar compositions for diseases like rheumatoid arthritis or certain oncological conditions.
- Validity of AR118856 may depend on distinguishing features over patented compounds or formulations in existing literature.
- The patent's scope could face restrictions if broad claims are challenged based on prior art showing similar chemistry or methods.
International Patent Position
- The patent's international strategic value hinges on whether it is part of broader IP rights such as via PCT applications.
- If similar patents exist or are pending elsewhere, geographic coverage may influence licensing, manufacturing, and commercial strategies.
Implications for Business and R&D
- Filing strategies should consider potential infringement risks based on existing patents.
- Licensing or collaboration opportunities may depend on the specific claims’ scope.
- To expand protection, filings in neighboring countries with similar patent landscapes, like Brazil or Chile, should reference AR118856, considering regional patent treaties.
Key Takeaways
- AR118856 claims protect a pharmaceutical composition or method with specific limitations tied to its active ingredient or process.
- The patent landscape in Argentina favors innovations targeting major therapeutic areas with active filings from international and local entities.
- Validity depends on non-obvious distinctions from prior art; ongoing legal challenges could impact enforceability.
- Strategic value hinges on broader regional patent portfolios, licensing opportunities, and the patent’s scope relative to existing IP rights.
FAQs
1. What is the potential duration of protection for AR118856?
It remains active for 20 years from its filing date, provided maintenance fees are paid.
2. Can the claims be challenged in Argentina?
Yes, through opposition or invalidation proceedings based on prior art, lack of novelty, or inventive step.
3. Does the patent cover all formulations of the active ingredient?
No, claims are limited to specific formulations or methods disclosed in the patent document.
4. Is patent protection in Argentina sufficient for commercialization?
Protection is confined to Argentina; for regional or international markets, additional filings are necessary.
5. How might AR118856 influence licensing deals?
The patent’s scope and validity will determine licensing scope and negotiation leverage within Argentina and potentially neighboring countries.
References
- Argentine Patent Office. (2022). Patent granted AR118856. accessed from https://www.inpi.gov.ar
- WIPO. (2022). Patent Landscape Reports for Latin America. https://www.wipo.int
- Argentine Patents Law No. 24,481. (2019).
- EPO Patent Database. (2022). Patent applications related to pharmaceuticals.
- USPTO. (2022). International Patent Applications and Patent Families.
